Oncotelic Therapeutics, Inc.
OTC: OTLC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vuong Trieu
- Employees
- 26
- Headquarters
- Agoura Hills, United States
- IPO year
- 1993
- Market cap
- $18.8M
- Website
- https://www.oncotelic.com
Loading OTLC…
Loading profile data…Frequently asked questions about OTLC
What does Oncotelic Therapeutics, Inc. (OTLC) do?
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cance...
Where does OTLC trade?
Oncotelic Therapeutics, Inc. (OTLC) trades on the Other OTC.
What sector is OTLC in?
Oncotelic Therapeutics, Inc. (OTLC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oncotelic Therapeutics, Inc.?
Vuong Trieu is the chief executive officer of Oncotelic Therapeutics, Inc. (OTLC).
Where is Oncotelic Therapeutics, Inc. headquartered?
Oncotelic Therapeutics, Inc. is headquartered in United States.
Does OTLC pay a dividend?
Oncotelic Therapeutics, Inc. (OTLC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OTLC go public?
Oncotelic Therapeutics, Inc. (OTLC) completed its initial public offering in 1993.